4. CONCLUSION
In vivo animal models are used to develop new drugs for curing several ailments. The newer drugs aim to provide alternatives with negligible or minimum side effects, with ease of availability, and at affordable prices to treat hepatic cirrhosis. The preclinical assessment of drugs is based on in vivo animal models specifically rodent or murine models. Further research is required to develop an ideal in vivo animal model which can be used for the assessment of drugs and in which animal recovery can be possible instead of animal sacrifice. Ex-vivo tissue culture techniques also aid in different stage evaluation of cirrhosis (either diet-influential or drug-induced liver damage. In future perspectives, the pathology of the individual patient could be studied by decellularisation of the liver and hepatic tissue bioengineering. A direct translation of animal experiments to human trials may not be possible due to species differences. Although animal models do not completely recapitulate human disease, animal models are still useful for answering specific questions regarding disease pathology, etiology, and testing therapeutic approaches that can be safely applied to patients. Researchers must choose the appropriate models for designing experiments because animal models are highly specific to a particular study. A distinct advantage of experimental animal models over in vitro cell culture systems is that they allow researchers to study cell biology through the observation of whole organs and living organisms. In this way, animal models provide researchers with unique opportunities to study cellular, molecular and histological features of hepatoxicity as well as to test novel therapeutics.